Project description:OvCaRe stands for Ovarian Cancer Research. OvCaRe formed in late 2000 when a group of Vancouver-based physicians and scientists joined with the common vision of enhancing ovarian cancer research in British Columbia and the explicit goal of improving outcomes for ovariant cancer patients. OvCaRe researchers are a multidisciplicary team, spanning basic to clinical science to allow for a true bench-to-bedside approach. OvCaRe was developed as a collaboration between the BC Cancer Agency, the Vancouver Coastal Health Research Insititute, and Hospital Foundation and BC Cancer Foundation

| EGAO00000000013 | EGA

British Columbia Cancer Agency

Project description:Organisation EGAO00000000169

| EGAO00000000169 | EGA

British Columbia Cancer Agency (BCCA), Genome Sciences Centre

Project description:The mandate of the Genome Sciences Centre at BCCA is to advance knowledge about cancer and other diseases, to improve human health through disease prevention, diagnosis and therapeutic approaches, and to realize the social and economical benefits of genomics and informatics research

| EGAO00000000002 | EGA

British Columbia Cancer Agency Branch

Project description:Organisation EGAO00000000145

| EGAO00000000145 | EGA

British Columbia Cancer Agency (BCCA), Department of Molecular Oncology

Project description:The Department of Molecular Oncology at BCCA in Vancouver, BC, Canada aims to characterise the molecular changes that occur as tumours develop

| EGAO00000000014 | EGA

Antihypertensive medications and risk of colorectal cancer in British Columbia.

Project description:Introduction: There is conflicting evidence for the association between antihypertensive medications and colorectal cancer risk, possibly reflecting methodological limitations of previously conducted studies. Here, we aimed to clarify associations between commonly prescribed antihypertensive medication classes and colorectal cancer risk in a large, retrospective, cohort study. Methods: Using linked administrative data between 1996 and 2017 from British Columbia, we identified a cohort of 1,693,297 men and women who were 50 years of age or older, initially cancer-free and nonusers of antihypertensive medications. Medication use was parameterized as ever use, cumulative duration, and cumulative dose. Cox proportional hazard models were used to estimate hazard ratios (HRs) and associated 95% confidence intervals (95% CIs) for associations of time-varying medication use [angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), beta-blockers (BBs), calcium channel blockers (CCBs), and diuretics] with colorectal cancer risk. Results: There were 28,460 incident cases of colorectal cancer identified over the follow-up period (mean = 12.9 years). When medication use was assessed as ever/never, diuretics were associated with increased risk of colorectal cancer (HR 1.08, 95% CI 1.04-1.12). However, no similar association was observed with cumulative duration or cumulative dose of diuretics. No significant associations between the other four classes of medications and colorectal cancer risk were observed. Conclusion: No compelling evidence of associations between antihypertensive medications and colorectal cancer were observed.

| S-EPMC10662292 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data